ANIXA BIOSCIENCES Reports Q3 2023 Earnings Results on September 6th

September 8, 2023

🌥️Earnings Overview

On September 6th, 2023, ANIXA BIOSCIENCES ($NASDAQ:ANIX) released their fiscal Q3 report for the 2023 year, which noted a total revenue of USD 0.0 million, a slight decrease from the same quarter in the prior year (USD 0.0 million). Net income reported for the quarter was USD -2.5 million, representing a smaller drop compared to the -2.8 million from the same quarter in the prior year.

Stock Price

On Wednesday, September 6th, ANIXA BIOSCIENCES reported its third quarter earnings results for 2023. The company’s financial performance in the third quarter remains uncertain and it is yet to be seen what repercussions it would have on the company’s stock performance in the upcoming weeks. Investors and analysts are keeping a close eye on ANIXA BIOSCIENCES to better understand the financial implications of the third quarter earnings report. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Anixa Biosciences. More…

    Total Revenues Net Income Net Margin
    0.21 -10.6 -5046.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Anixa Biosciences. More…

    Operations Investing Financing
    -5.83 -14.93 -0.3
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Anixa Biosciences. More…

    Total Assets Total Liabilities Book Value Per Share
    26.58 1.99 0.82
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Anixa Biosciences are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -22.8% -5509.0%
    FCF Margin ROE ROA
    -2777.6% -27.6% -27.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently completed an analysis of ANIXA BIOSCIENCES‘ financial and business wellbeing. We determined that ANIXA BIOSCIENCES is a medium risk investment. After examining the income sheet, balance sheet, and cashflow statement, we have identified three risk warnings. If you’re considering investing in ANIXA BIOSCIENCES, we highly recommend taking a closer look at these three warning signs. To do this, register on goodwhale.com. We’ve made it easy to access and analyze this company’s financial information. At GoodWhale, we prioritize the security of our users’ investments. We want our users to make informed decisions with the best financial data available. With our user-friendly platform, you can access the details you need to make a confident decision about ANIXA BIOSCIENCES. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    It is one of several companies in the field, such as Adicet Bio Inc, Indaptus Therapeutics Inc, and Celldex Therapeutics Inc, that are dedicated to researching and developing innovative treatments for a variety of illnesses.

    – Adicet Bio Inc ($NASDAQ:ACET)

    Adicet Bio Inc is a biotechnology company that develops allogeneic, off-the-shelf adoptive cell therapies for the treatment of cancer, autoimmune, and infectious diseases. As of 2022, it has a market cap of 330.81M, which indicates that the company is worth less than its peers in the biotech sector. Its Return on Equity (ROE) of -11.39% also shows that it has not been able to generate profits from the investments it has made. This could be due to a variety of factors, such as high research and development costs, limited access to capital, or a lack of product market fit.

    – Indaptus Therapeutics Inc ($NASDAQ:INDP)

    Indaptus Therapeutics Inc is a biotechnology company focused on the discovery and development of new treatments for rare diseases. The company has a current market cap of 11.51M as of 2022, which is a good indication of the potential of their current products and future products in development. Additionally, their Return on Equity (ROE) of -20.9% indicates that the company is not generating any profits from its investments, however this can be seen as an opportunity for investors to get in at a low price and gain when the company does turn a profit.

    – Celldex Therapeutics Inc ($NASDAQ:CLDX)

    Celldex Therapeutics Inc is a biopharmaceutical company that focuses on the development, manufacture and commercialization of immunotherapy-based treatments for cancer and other diseases. Its market cap as of 2022 was 2.05 billion dollars and its Return on Equity (ROE) was -17.56%. The market cap is a measure of the company’s value and indicates the amount of capital invested in the company. A negative ROE means that the company is not generating enough profit compared to its equity, which could be a sign of potential financial distress. Celldex Therapeutics Inc is striving to create innovative immunotherapy treatments that can improve the lives of patients suffering from cancer and other diseases.

    Summary

    Anixa Biosciences reported their Q3 fiscal year 2023 earnings on September 6, 2023. Total revenue decreased slightly from the same period in the prior year, and net income was lower than the prior year as well. Investors may want to consider the company’s short-term performance when investing in Anixa Biosciences.

    The company’s performance and guidance for future quarters will be important to consider. Long-term investors should look at the company’s financials, competitive positioning, and other metrics to determine if Anixa Biosciences is a good investment opportunity.

    Recent Posts

    Leave a Comment